Numerous studies suggest n-3 polyunsaturated fatty acids (n-3 PUFA) and oleic acid intake have bene¢cial e¡ects on health including risk reduction of coronary heart disease.The purpose of this study was to evaluate the e¡ect of a commercially available skimmed milk supplemented with n-3 PUFA, oleic acid, and vitamins E, B 6 , and folic acid (Puleva Omega3 s ) on risk factors for cardiovascular disease. (CVD). Methods:Thirty volunteers were given 500 ml/day of semi-skimmed milk for 4 weeks and then 500 ml/day of the n-3 enriched milk for 8 further weeks. Plasma and LDL lipoproteins were obtained from volunteers at the beginning of the study (T pre ), and at 4, 8 and 12 weeks.
Introduction
Cardiovascular disease (CVD) is the leading cause of death in Europe, the US and a major part of Asia. A variety of risk factors are associated with CVD, including high cholesterol levels, high plasma levels of homocysteine, hypertension, diabetes, low HDL-cholesterol levels and low levels of antioxidants, most of them influenced by diet (1) . Beneficial effects of the Mediterranean diet on CVD are related to reduced saturated fat and high olive oil consumption (rich in oleic acid) and also to a high intake of fruit and vegetables, all of them rich in antioxidants. The consumption of monounsaturated fatty acids (MUFAs), especially oleic acid, has been shown to decrease plasma triacylglycerol and cholesterol concentrations, without affecting plasma HDL-cholesterol levels in healthy normolipidaemic subjects (2, 3) .
A considerable number of research studies focus on CVD prevention by n-3 polyunsaturated fatty acids (n-3 PUFAs), namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). n-3 PUFAs favourably affect atherosclerosis, coronary heart disease, inflammatory disease, and perhaps even behavioural disorders (4) . Dietary n-3 PUFA have been reported to prevent CVD through a variety of actions. As they are incorporated into the cellular phospholipids, they produce less active forms of eicosanoids precursors with important physiological implications. Although the exact mechanism by which n-3 fatty acids exert an atheroprotective effect is still unclear, they present anti-inflammatory properties, prevent arrythmia, inhibit the synthesis of cytokines and mitogens, stimulate endothelial-derived nitric oxide, lower blood lipids and also inhibit atherosclerosis and thrombosis (5) (6) (7) (8) .
Atherosclerosis and inflammation share similar mechanisms in their early phases, involving increased interactions between vascular endothelia and circulating leukocytes, where vascular cell adhesion molecule 1 (VCAM-1) and intercellular cell adhesion molecule 1 (ICAM-1) play major roles (9) .
Several studies suggest plasma levels of these adhesion molecules constitute a good marker for long-term prediction of cardiovascular events (10, 11) . In this 2002.0620 sense, there is growing evidence regarding the effect of fish oils showing that they act modulating endothelial function (11) by reducing expression of endothelial adhesion molecules (VCAM-1 and ICAM-1) (12, 13) .
Epidemiological studies have shown that high blood concentration of homocysteine appears to be associated with higher risks of coronary, cerebral, and peripheral vascular disease and are inversely related to blood levels of folate and of vitamins B 12 and B 6 (14) . This indicates coronary heart disease risk being reduced by dietary vitamin supplementation (15) . Furthermore, a study carried out in healthy young women showed that doses of folic acid as low as 250 mg/day, in addition to usual dietary intakes of folic acid, significantly decreased plasma levels of homocysteine (16) .
As a result, health authorities have recommended increases in the consumption of PUFAs (17) (18) (19) , in which fish oil is specially rich. However, modern Western societies tend to include very little fish in their diets and increasing fish consumption would involve major dietary changes, which makes this approach not very effective. Therefore, other ways to increase consumption of PUFAs have to be explored and assessed at a community or clinical level (20) Milk has been shown to be the most efficient vehicle for fat absorption because milk fat appears highly dispersed in micelles. We have used milk as a vehicle for n-3 PUFA, oleic acid, and vitamins E, B 6 , and folic acid supplementation. The objective of the present work was to study the effects of this product on risk factors for CVD in young healthy normolipidaemic subjects.
Materials and methods

Subject and study design
Thirty volunteers (15 men and 15 women, age 33.17 7.2, range: 20-45 years) who were resident in Spain participated in the study. Volunteers were defined as healthy normolipidaemic subjects after consulting medical history and carrying out a physical examination. No subject was taking any medication known to influence lipid metabolism 1 month before the study and they were not suffering from any chronic or metabolic disease. Women volunteers were not using oral contraceptives. Volunteers were instructed not to change their physical activity and their usual diet, but only to avoid eating fish from the beginning until the end of the study. The protocol was approved by the Ethical Committee of Puleva Biotech S.A., and informed written consent was obtained from the subjects. All of the subjects completed the study and not one missed a sampling date. Volunteers were also requested to fill in a food diary according to instructions from the principal investigator where they registered all food consumption during the study. The amounts of oleic acid and n-3 fatty acids coming from sources other than the milks were calculated using the food composition tables published in (21) as reference values.
The subjects drank 500 ml/day of semi-skimmed milk enriched in vitamins A and D from the beginning of the study (T pre ) for 4 weeks (T 0 ). At time T 0 , subjects replaced the semi-skimmed milk with 500 ml/day of the n-3 enriched milk, a dairy product containing oleic acid and polyunsaturated fatty acids (PUFA) of the n-3 series, vitamins A, D, E, B 6 and folic acid (Tables 1-4) . After an overnight fast lasting 10 h, a blood sample (30 ml) was taken at times T pre (beginning of the study), T 0 (after consumption of the semi-skimmed milk) and then, at 4 and 8 weeks during consumption of the n-3 enriched milk (T 4 and T 8 , respectively).
Plasma and LDL isolation
Blood was withdrawn in EDTA-containing vacutainers (S-Monovette, Sarstedt, Germany) and plasma was obtained by centrifugation at 1000g for 10 min at 41C. For LDL isolation, 10 ml of fresh plasma was transferred to ultracentrifuge tubes and density was adjusted to 1.30 g/ml by addition of solid KBr. Tubes were then filled up dropwise with a 0.15 M NaCl solution and centrifuged at 242,000g for 2.5 h at 41C in a VTi50 rotor as described in (22) . LDL particles typically sedimented at density range 1.006-1.063 g/ml as described elsewhere. LDL fractions were pooled and dialysed in the dark for 24 h against three changes of 2 l each of 0.01 M phosphate-buffered saline (PBS) 0.15 M NaCl, pH 7.4, and then frozen at À801C under nitrogen atmosphere until needed.
Plasma and lipoprotein lipid peroxidation
Fresh plasma (50 ml) was incubated with 100 mM of the free radical generator AAPH (2, 2 0 -azobis-2-amidinopropane hydrochloride, Wako Chemical Industries Ltd, Japan), at 371C for 2 h. AAPH is a widely used azo compound that produces peroxyl radicals at a constant rate. Plasma lipid peroxidation was determined by measuring TBARS as described in (23) .
For lag time measurements, 50 mg of dialysed LDL in 1 ml PBS was incubated with 10 mM CuSO 4 for several hours at 371C. The formation of conjugated dienes was monitored continuously by measuring the increase in absorbance at 234 nm every 10 min. Lag time was determined according to (24) . LDL lipid peroxidation was determined before and after AAPH induction as described in (25) .
Total antioxidant capacity
Total antioxidant capacity was measured in plasma using Trolox as standard (26) . Briefly, 20 ml of fresh plasma were 1:1 diluted in PBS and incubated with 1 ml of ABTS+ for 20 min. Absorbance was read at 734 nm. ABTS cation was prepared by addition of 88 ml of 140 mM potassium persulphate to 5 ml of a 7 mM solution of ABTS (Sigma A-1808) in water and incubation for 12-14 h. Working solution was obtained by dilution of the former with PBS until the aborbance at 734 nm was 0.7 7 0.02 as described in (27) .
Lipids, homocysteine, vitamin B 12 , vitamin E, folate and VCAM-1, ICAM-1 determinations Plasma triacylglycerols, total cholesterol, and HDL cholesterol were measured using commercial kits purchased from Biosystems (Barcelona, Spain) according to the manufacturer's instructions. Plasma fatty acid profile was determined by gas-liquid chromatography as described in (28) . Total plasma homocysteine concentration was measured by HPLC with fluorescence detection (29) . Plasma vitamin E concentration was determined by HPLC with ultraviolet detection following the method described by Thurnham et al. (30) . Plasma folic acid and vitamin B 12 concentration were measured by immunoassay using a commercial kit (SimulTRAC-SNB Radioassay Kit, ICN Pharmaceuticals, USA). VCAM-1 and ICAM-1 were measured using a commercial kit from Biosource International (USA) according to the manufacturer's instructions.
Statistical analysis
All data are expressed as means 7 SEMs. Comparisons between groups at the different time points were assessed 
Results
Both types of milk were well accepted and compliance was good. There was no significant body weight change in the volunteers throughout the study.
Dietary intake of fatty acids
Composition and fatty acid profile of the semi-skimmed and n-3 enriched milks used in the study are given in Tables 1 and 2 . The amounts of oleic acid, DHA and EPA supplemented in 500 ml of the n-3 enriched milk were 5.12, 0.13, and 0.2 g, respectively, whereas the semi-skimmed milk contained only 1.82 g/500 ml, and no detectable levels of DHA and EPA. The n-3 enriched milk contained more than 8 times the amounts of PUFAs contained in the semi-skimmed milk and more than twice the amount of MUFAs, whereas levels of saturated fatty acids detected in the n-3 enriched milk are reduced by 3 times compared to the semi-skimmed milk used in the study. Excluding the test milk, the diet consumed by volunteers throughout the study contained negligible levels of DHA and EPA as they were instructed to avoid fish consumption or fish-derived products. Dietary contribution calculated for oleic acid and linolenic acid coming from foods other than the milks were 22 g and 300 mg/day in average, respectively.
Fatty acid composition of plasma
Average levels of major plasma fatty acids detected in the volunteers of the study are given in Table 3 .
Abstinence from fish consumption during 1 month during the first period of the study did not significantly change plasma fatty acid profile although a moderate decrease in plasma levels of EPA and DHA was found. The first 4-week period of semi-skimmed milk supplementation, together with dietary exclusion of fish throughout the study are likely to be responsible for the reported decrease, as the subjects of the study were recruited from southern Spain, where fish consumption is usually moderate to high. However, 8-week supplementation with the n-3 enriched milk used in the study not only restored initial levels of plasma EPA and DHA but increases of 33% and 30% were obtained, respectively. Plasma levels of the rest of fatty acids measured did not significantly change at the time points tested, compared to levels detected at the beginning of the study (Table 3) . Fatty acid composition in LDL particles was also measured at the times of the study but no significant change in the fatty acid profile was found compared to fatty acid composition of plasma (not shown).
Plasma lipids
Plasma lipid values measured in volunteers at the different times of the study are given in Table 4 . Four weeks of semi-skimmed milk consumption produced mild increase, although no significant, in values of total and LDL cholesterol and there was a decrease in HDL cholesterol levels, most likely due to the effect of the saturated fat contained in this type of milk (ca 70%). The 2-month consumption of the n-3 enriched milk was associated with a total cholesterol significant reduction of about 6% (Po0.05). The effect on LDL cholesterol was more pronounced as values were significantly reduced at T 8 by more than 16% (Po0.05) compared to initial values (T pre ), and more than 19% when compared to T 0 . The LDL cholesterol decrease observed at times T 4 and T 8 was linear from T 0 , which suggests that the decrease might have been more pronounced if the study had been carried out for a longer period of time. n-3 Enriched milk consumption also produced a mild but not statistically significant linear increase on HDL-cholesterol values at times T 4 and T 8 , which becomes clearer when compared to T 0 . With regard to triglyceride levels found in plasma, periods of either semi-skimmed or n-3 enriched milk consumption produced no significant changes at the times of the study.
Vitamin E, plasma and LDL oxidation parameters
Total antioxidant capacity, TBARS induced with the free radical generator AAPH, and vitamin E were measured in plasma (Table 4 ) and no significant differences were found in any of these parameters at the times of the study. The effect of the n-3 enriched milk consumption on oxidability of LDL particles isolated from volunteers of the study differ from the ones obtained in plasma (Table 5) . Two-month consumption of n-3 enriched milk resulted in a significant 12% (Po0.05) reduction of LDL hydroperoxides. Lag time, or the time required for an oxidant to induce the propagation phase of oxidation in LDL, indicates susceptibility of LDL to oxidation. Lag time values were significantly increased by 27% (Po0.05) at T 8 , suggesting that LDL particles do not become more prone to oxidation upon consumption of n-3 enriched milk. However, vitamin E concentration measured in LDL showed mild but no statistically significant increase at T 8 .
Plasma levels of ICAM-1, VCAM-1
Plasma concentrations of soluble forms of ICAM-1 and VCAM-1 at the different times of the study are shown in Table 4 . We observed a significant 16% (Po0.05) gradual reduction in VCAM-1 values after 2 months consumption of n-3 enriched milk (T 8 ), compared to initial levels and T 0 . This type of milk also tended to decrease the expression of ICAM-1 by more than 10% but this decrease was not statistically significant when compared to values at T pre or T 0 .
Homocysteine and folic acid
Results show 2-month intake of the n-3 enriched milk produced a significant 13% reduction (Po0.05) in plasma levels of homocysteine (Table 6 ). Results also show that folic acid from the supplemented milk was bioavailable and produced a significant 75% and 91% increase of folic acid concentration in plasma at times T 4 and T 8 , respectively. Plasma vitamin B 12 concentrations were increased at time T 8 compared to those observed at times T pre , T 0 and T 4 .
Discussion
Milk has been shown to be a very efficient vehicle for fat absorption because milk fat appears highly dispersed in very small micelles. In this sense we used milk, an every day used drink, as a carrier for PUFAs, MUFAs and vitamin supplementation to try to increase the intake of those, and further studied their effects on risk factors for CVD in healthy volunteers.
Total amounts of EPA and DHA contained in 500 ml of the n-3 enriched milk were 133 and 200 mg, respectively (daily intake for 2 months). These levels roughly exceed the amount of EPA + DHA contained in the UK average serving portion of cod (31) . Two months administration of the n-3 enriched milk resulted in a significant (about 30%) increase in DHA and EPA plasma levels. Similar results were obtained by others when semi-skimmed milk was supplemented with similar amounts of PUFAs (32) . Fatty acid composition of plasma fatty acids is consistent with LDL fatty acid profile.
PUFAs on their own are very susceptible to being oxidised and quickly react when oxidants or oxidising conditions are present. The n-3 supplemented milk used in the study contained 7.5 mg vitamin E per 500 ml, which represents 75% of the recommended vitamin E daily intake. We addressed the question of whether regular intake the PUFAs enriched milk used in the study would make plasma and LDL particles more prone to oxidation, or else, if they would reduce levels of endogenous antioxidants to consider possible deleterious effects derived from consumption. n-3 Supplemented milk consumption did not produce an increase in any of the plasma oxidation parameters analysed. Possible explanations for these results could either be due to the amount of PUFAs being too low to induce changes in plasma oxidability and/or a compensation effect derived from vitamin E supplementation, which in turn may have counteracted oxidation effects. Although vitamin E was supplemented in the n-3 enriched milk to provide ca 75% of the recommended daily intake, we did not detect any significant increase in plasma vitamin E levels. This is not surprising as several other research studies show that much higher levels of vitamin E either supplemented in milk or in capsules do not produce significant increase in plasma levels (33) .
Plasma concentration of triglycerides did not change upon consumption of the n-3 enriched milk whereas a modest non-significant increase on HDL cholesterol was found. Average plasma triglyceride values obtained for volunteers at the beginning of the study (1.2270.05 mmol/l) were below average levels reported for normolipidaemic subjects (1.58 mmol/l, range 0.34-2.82 mmol/l). This suggests daily supplementation with 500 ml of n-3 enriched milk, only containing 333 mg of EPA+DHA, is not enough to reduce triglyceride levels in the volunteers of the study, and that there was probably a threshold level we should have gone beyond to have been able to exert an effect. Visioli et al. (32) carried out a similar research study describing reductions of up to 19% in plasma triglyceride values and 19% increase in HDL-cholesterol levels after 6-week consumption of milk enriched only with n-3 PUFA that supplemented 400 mg of n-3 fatty acids per day. Interestingly, a similar effect in plasma triglyceride reduction and HDL increase was only reached by Cobiac et al. (34) over a 5-week period of daily administration of 4.5 g DHA+EPA in mildly hyperlipidaemic males. Fat milk is highly dispersed in micelles and is known to be very efficiently absorbed in the gut, so the administration of n-3 PUFA supplemented in the test milk may be responsible for the relatively high levels found in plasma and the effects shown. Moreover, the n-3 enriched milk used in our study contained almost 3 times the amount of oleic acid occurring in standard milk, which, in combination with PUFAs, produced desirable LDL and total cholesterol lowering effects. Particularly, the LDL cholesterol 16% reduction found in our study has, to our knowledge, never been reported before for any supplemented milk. Total and LDL cholesterol lowering effects of oleic acid and PUFAs have been extensively described (3, and references therein) and are associated with a wide range of physiological effects. Indeed, free radical generation and lipid peroxidation are positively correlated with plasma total cholesterol concentration (35) and LDL cholesterol is also associated with increased susceptibility of LDL particles to oxidation (36) . This may also explain the increase found in LDL lag time values (27%) found at T 8 of the study, when vitamin E concentration measured in LDL remained mostly unchanged throughout the study. In this sense, alpha-tocopherol is in quantitative terms the major antioxidant among those present in LDL and is, therefore, considered the first line of defence against oxidation (37) . It has been shown that LDL resistance to oxidation not only depends on alphatocopherol content but also in other variables yet to be identified (38) . In this sense, retinol has also been shown to have important effects on increasing LDL resistance to oxidation (39) . Both types of milk used in the study were enriched in equal amounts of vitamin A (see Table  1 ), and intake of this vitamin by the volunteers of the study supposed more than 75% of the recommended daily intake, over and above that already present in their diets. This fact may explain the 18% increase in lag time values also detected during the first period of semiskimmed milk consumption, and the constant levels of LDL vitamin E throughout the study. However, the fact that LDL lag time is increased by 27%, though statistically significant, is perhaps too low to accept a meaningful clinical correlation (40), so we conclude the n-3 enriched milk tested does not increase significantly plasma oxidability of LDL.
The folic acid supplemented in the n-3 enriched milk produced an increase of more than 90% in plasma levels of this vitamin at T 8 of the study. Vitamin B 6 was also supplemented in n-3 enriched milk but not in semiskimmed milk. Homocysteine-lowering effects of folic acid and vitamin B 6 have been well documented (41, 42) , and also folic acid has been shown to reverse endothelial disfunction in animal models (43) , suggesting vitamins supplemented in n-3 milk may have significantly contributed to reducing homocysteine levels in plasma.
Many clinical and epidemiological studies have shown that high plasma levels of homocysteine is an independent risk factor for CVD (1) . Possible mechanisms of homocysteine-induced atherosclerosis include endothelial dysfunction, promotion of lipoprotein oxidation and increased cholesterol synthesis in hepatocytes (44) (45) (46) . Recently, homocysteine has been described to stimulate the transcription factor nuclear factor kB (NF-kB), causing a pleiotropic response which involves upregulation of endothelial activation factors such as VCAM-1. Reactive oxygen species (ROS) and oxidative stress are well-known activators of NF-kB (9) . Homocysteine has been demonstrated to promote ROS production by a number of mechanisms including inhibition of glutathion peroxidase, one of the most important antioxidant defences (47) . Consistent with this, the significant reduction in plasma concentration of homocysteine found in our study may influence: (1) VCAM-1 levels, as the latter seems to be induced by the former via ROS and NF-kB, as described above; (2) the absence of changes in plasma and LDL oxidability found in the study, and (3) at least in part, the cholesterol reduction.
In agreement with our results, Yaqoob et al. (48) observed a decrease in plasma levels of adhesion molecules after 2-month consumption of a MUFA-rich diet. However, we found differences in the expression pattern of VCAM-1 and ICAM-1. A major role for VCAM-1 but not for ICAM-1 has been found in early atherosclerosis (49 and references therein). Both VCAM-1 and ICAM-1 are expressed by aortic endothelium in regions predisposed to atherosclerosis and are both up-regulated in hypercholesterolaemic animals. Their expression patterns are different, however, which suggests different functions for both molecules in lesion initiation. This may also explain the differences in the plasma concentration of VCAM-1 and ICAM-1 found in our study, which were increased by 16% (Po0.05) and 10%, respectively. A very recent study also reported that fish oil supplementation (1.2 g DHA+EPA) in human volunteers for 12 weeks significantly decreased (20% in average) plasma VCAM-1 concentrations whereas ICAM-1 concentrations were not affected by the fish oil treatment (13) .
Various research studies show that the intake of a range of foods and ingredients, including milk, enriched with alpha-linoleic acid, EPA and DHA can be used to achieve desired biochemical effects without the ingestion of supplements or changing dietary habits (20, 32) .
In conclusion, dietary consumption of the n-3 supplemented milk tested in our study is an effective way to increase consumption of PUFAs also having favourable effects on risk factors for CVD. Further studies with this type of milk investigating their effects in older populations and in patients with high risk factors for CVD are under way in our laboratory.
